NTT-DOCOMO
16.1.2024 10:11:27 CET | Business Wire | Press release
NTT DOCOMO, INC. announced today that it will exhibit at MWC Barcelona 2024, the world's largest mobile exhibition, in Barcelona, Spain from February 26 to 29. DOCOMO's booth will showcase exhibits of its technological advancement since last year and presentations focused on the core themes of 6G, open radio access networks (Open RAN) and extended reality (XR), aiming to advance international standardization and foster global business opportunities with the implementation of next-generation communication technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116090399/en/
NTT DOCOMO Booth at MWC Barcelona 2024 (Graphic: Business Wire)
For 6G, there will be interactive demonstrations of FEEL TECH,® an innovative technology that revolutionizes the sharing of sensory information between people DOCOMO's Human Augmentation Platform connected to a 6G network. This pioneering technology aims to facilitate clear transmission of sensory information that is often difficult to communicate verbally, paving the way for a new communication culture and providing added value for an enhanced quality of life.
The booth will also provide a glimpse of the coming world of 6G and advanced wireless technologies that DOCOMO is now developing, such as a non-terrestrial network (NTN) incorporating high-altitude platform stations (HAPS),1 which are expected to facilitate the broad extension of communication services beyond the reach of conventional terrestrial network areas, from remote seas to low-orbit space.
For Open RAN, in addition to presenting the OREX®2-branded services (OREX Packages), DOCOMO will introduce the latest initiatives with diverse global vendors and operators since the launch of the OREX to make Open RAN a reality.
For XR, DOCOMO will showcase the first concept model3 of XR glasses from NTT QONOQ Devices, INC.,4 which is scheduled for release around mid-2024, along with images of utilization.
At MWC Barcelona 2024, DOCOMO looks forward to showcasing its cutting-edge technologies and businesses the company is developing under the brand slogan "changing worlds with you."
For more about DOCOMO's exhibits and the overall exhibition, please refer to the appendix.
1 Unmanned vehicles flying in the stratosphere for days or months at a time, using relays to provide mobile connectivity (ranging up to 200 kilometers) in mountainous and remote areas, including at sea and in the air, on a highly cost-efficient basis.
2 OREX Announces OREX® Open RAN Service Lineup https://www.docomo.ne.jp/english/info/media_center/pr/2023/0927_00.html
3 Specifications of final commercial products may differ from the reference exhibits.
4 NTT QONOQ, INC. and SHARP CORPORATION form a joint venture company, NTT QONOQ Devices, INC.
https://www.devices.nttqonoq.com/pdf/20230327.pdf
Human Augmentation Platform, FEEL TECH and OREX are registered trademarks of NTT DOCOMO, INC. in Japan.
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 88 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/
Appendix
Overview of NTT DOCOMO Booth at MWC Barcelona 2024
1. Exhibitions |
||
Theme |
Exhibit & Demo |
Details |
6G |
Wireless technologies and NTN |
Non-terrestrial network initiatives for 6G and extended coverage, including technical explanations, dioramas and simulators. |
Human Augmentation Platform |
Platform and FEEL TECH technology for sharing sensory information between people. |
|
Open RAN |
Virtual tour of Shared Open Lab |
360-degree, 3D virtual tour of the OREX verification environment. |
Automated network design and maintenance |
Demonstrations of actual systems for automated network design and maintenance. |
|
XR |
Conceptual model of XR glasses |
Mock-up model and video illustrating how these proposed glasses will be used. |
2. NTT DOCOMO Booth Location
Hall 4 Stand 4E50
3. Presentation
Tentative title: Open RAN: Toward Commercialization and Operations
When: Monday, February 26 from 13:15 to 13:45 (local time)
Where: Broadcast Stage, Hall 4
Speaker: Mr. Sadayuki Abeta, OREX evangelist, NTT DOCOMO
Note: Content and schedule are subject to change. Please see MWC Barcelona 2024 for the latest information.
Reference
MWC Barcelona 2024
https://www.mwcbarcelona.com/
1. Dates & Times
February 26 to 29
08:30 to 19:00, but 08:30 to 16:00 on last day (all times local)
2. Venue
Fira Gran Via
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat
Barcelona, Spain
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116090399/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
